Noninvasive ventilation: has Pandora’s box been opened?

Other

(2249) Views  (826) Full article downloads

Authors: Ari Manuel, Richard EK Russell, Quentin Jones

Published Date February 2010 Volume 2010:5 Pages 55 - 56

DOI: http://dx.doi.org/10.2147/COPD.S9343

Ari Manuel¹, Richard EK Russell², Quentin Jones³

¹Department of Respiratory Medicine, High Wycombe Hospital, Bucks, UK; ²Airway Disease Section, National Heart and Lung Institute, Imperial College, London, UK; ³Specialist Registrar, Department of Respiratory Medicine, Churchill Hospital, Oxford

Exacerbations of COPD are the largest single cause of hospital admission with respiratory disease, and are frequently associated with impaired gas exchange and mortality rates of up to 14%. Acute hypercapnic respiratory failure leads to admissions to intensive care units with a mortality rate of 59% at one year. Noninvasive ventilation (NIV) is a well established and validated therapy for acidotic hypercapnia respiratory failure in COPD, a leading cause of global mortality and morbidity. The use of NIV in patients with acute type II or chronic respiratory failure has increased over the past 10 years.